Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-week randomised, double-blind, parallel-group trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetes

Next Previous
Trial Profile

A 6-week randomised, double-blind, parallel-group trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms onset 4
  • Sponsors Novo Nordisk

Most Recent Events

  • 29 Sep 2017 According to a Novo Nordisk media release, the US FDA has approved Fiasp for glycemic control in adults with tyep1 and type 2 diabetes based on data from this and other three trials ((231999, 226655, 232775 trials from ONSET programme).
  • 10 Jan 2017 According to a Novo Nordisk media release, the European Commission has granted marketing authorization for Fiasp for the treatment of diabetes in adults based on data from this and other three trials (231999, 226655, 232775 trials from ONSET programme).
  • 06 Jan 2017 According to a Novo Nordisk media release, Fiasp has received marketing authorization from Health Canada.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top